Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years

详细信息    查看全文

• 作者：Arne Kolstad¹ ; ^{arnek@ous-hf.no} ; Lone Bredo Pedersen² ; Christian W. Eskelund² ; Simon Husby² ; Kirsten Grø ; nbæ ; k² ; Mats Jerkeman³ ; Anna Laurell⁴ ; Riikka Rä ; ty⁵ ; Erkki Elonen⁵ ; Niels Smedegaard Andersen² ; Peter deNully Brown² ; Eva Kimby⁶ ; Hans Bentzen⁷ ; Christer Sundströ ; m⁸ ; Mats Ehinger⁹ ; Marja-Liisa Karjalainen-Lindsberg¹⁰ ; Jan Delabie¹¹ ; Elisabeth Ralfkiæ ; r¹² ; Unn-Merete Fagerli¹³ ; Herman Nilsson-Ehle¹⁴ ; Grete Fossum Lauritzsen¹ ; Outi Kuittinen¹⁵ ; Carsten Niemann² ; Christian Hartman Geisler² ; for the Nordic Lymphoma Group
• 关键词：Mantle cell lymphoma ; Autologous stem cell transplantation ; Minimal residual disease ; Preemptive rituximab
• 刊名：Biology of Blood and Marrow Transplantation
• 出版年：2017
• 出版时间：March 2017
• 年：2017
• 卷：23
• 期：3
• 页码：428-435
• 全文大小：1934 K
• 卷排序：23

文摘

Minimal residual disease (MRD) relapse predicts clinical relapse after autologous stem cell transplantation (ASCT) in mantle cell lymphoma. Continuous MRD negativity predicts favorable outcome. MRD positivity at first analysis post-ASCT predicts very poor outcome. Preemptive rituximab therapy converts patients back to MRD-negative. Preemptive rituximab treatment likely delays clinical relapse.